Every once in a while a discovery in the clinic exceeds researchers’ expectations. This is what happened in early February 2022 when Vicore, received early data from a Phase 2 study of our candidate product, C21, for idiopathic pulmonary fibrosis (IPF).
Article published in MedNous (Vol 16, No 3, March 2022)
C21 shows promise against COVID-19 where other drugs have failed
Patient insights to shape development of a dCBT for IPF patients
Untangling the dualistic components of the RAS in PF the Yin and Yang
Vicore’s ATTRACT study shows promise for novel drug C21 against COVID-19 in hospitalised patients
Interview with Ella Radvogin, Clinical Psychologist at Alex Therapeutics
Science